Promises of apoptosis-inducing peptides in cancer therapeutics.

Détails

Ressource 1Télécharger: 5_21470140_Postprint.pdf (256.57 [Ko])
Etat: Public
Version: Final published version
Document(s) secondaire(s)
Télécharger: 5_21470140_Postprint.pdf (590.48 [Ko])
Etat: Public
Version: Author's accepted manuscript
ID Serval
serval:BIB_6603E02C972C
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Promises of apoptosis-inducing peptides in cancer therapeutics.
Périodique
Current Pharmaceutical Biotechnology
Auteur⸱e⸱s
Barras D., Widmann C.
ISSN
1873-4316 (Electronic)
ISSN-L
1389-2010
Statut éditorial
Publié
Date de publication
2011
Volume
12
Numéro
8
Pages
1153-65
Langue
anglais
Résumé
Until recently, most research efforts aimed at developing anti-cancer tools were focusing on small molecules. Alternative compounds are now being increasingly assessed for their potential anti-cancer properties, including peptides and their derivatives. One earlier limitation to the use of peptides was their limited capacity to cross membranes but this limitation was alleviated with the characterization of cell-permeable sequences. Additionally, means are designed to target peptides to their malignant targets. Most anti-cancer peptidic compounds induce apoptosis of tumor cells by modulating the activity of Bcl-2 family members that control the release of death factors from the mitochondria or by inhibiting negative regulators of caspases, the proteases that mediate the apoptotic response in cells. Some of these peptides have been shown to inhibit the growth of tumors in mouse models. Hopefully, pro-apoptotic anti-tumor peptides will soon be tested for their efficacy in patients with cancers.
Pubmed
Web of science
Création de la notice
05/09/2011 8:29
Dernière modification de la notice
20/08/2019 14:21
Données d'usage